Back Number
2021
- December 14 Top-line Results of Phase 3 Clinical Study of JTE-052 Ointment, JAK Inhibitor, in Infant Patients with Atopic Dermatitis in Japan（PDF）
- May 26 Listing on the Japanese National Health Insurance Drug Price List and Launch of CORECTIM® Ointment 0.25% in Japan（PDF）
- April 21 Listing on the Japanese National Health Insurance Drug Price List and Launch of ORLADEYO Capsules 150mg for Suppression of HAE Attacks in Japan（PDF）
- March 23 JT Receives Approvals of CORECTIM® Ointment 0.25% and CORECTIM® Ointment 0.5% for the Treatment of Pediatric Atopic Dermatitis in Japan（PDF）
- March 23 JT Receives Approval for Additional Indication for Iron Deficiency Anemia for Riona® and Promotion to Start in Japan（PDF）
- March 17 Torii has entered into License Agreement with Verrica Pharmaceuticals to Develop & Commercialize VP-102 in Japan（PDF）
- January 22 OrphanPacific Inc.Receives Manufacturing and Marketing Approval of ORLADEYOCapsules150mg for Suppression of HAE Attacksin Japan（PDF）
2020
- November 18 Listing on the Japanese National Health Insurance Drug Price List and Launch of ENAROY® Tablets 2mg･4mg for the Treatment of Anemia Associated with Chronic Kidney Disease in Japan（PDF）
- September 25 JT Receives Manufacturing and Marketing Approval of ENAROY® Tablets 2mg・4mg for the Treatment of Anemia Associated with Chronic Kidney Disease in Japan（PDF）
- August 5 Torii has entered into Option Agreement with Verrica Pharmaceuticals to Develop & Commercialize VP-102 in Japan（PDF）
- June 1 Torii and ASKA Enter into Co-Promotion Agreement Concerning Additional Indication of Iron Deficiency Anemia for Riona®（PDF）
- May 29 JT Files New Drug Application of JTE-052 Ointment, JAK inhibitor, for the Treatment of Pediatric Atopic Dermatitis in Japan（PDF）
- May 15 JT Files for Additional Indication for Riona®, Ferric Citrate Hydrate, for Iron Deficiency Anemia in Japan（PDF）
- April 22 Listing on the NHI Drug Price List and Launch of CORECTIM® Ointment 0.5% for the Treatment of Atopic Dermatitis in Japan（PDF）
- March 18 Company Spin-Off (Short-Form Absorption-Type Company Split) and Share Transfer of a Newly Founded Subsidiary with Transfer of Sakura Plant（PDF）
- February 6 Progress of the Medium-Term Management Plan 2021 and Revision of the Targets（PDF）
- January 23 JT Receives Manufacturing and Marketing Approval of CORECTIM® Ointment 0.5% for the Treatment of Atopic Dermatitis in Japan（PDF）
- January 15 Torii Signs Exclusive License Agreement with JT for Development and Commercialization of Tapinarof in Japan（PDF）
2019
- November 29 JT Files New Drug Application of Enarodustat (JTZ-951), for the Treatment of Anemia Associated with CKD in Japan（PDF）
- November 25 Transfer of rights to uricosuric agent URINORM®（PDF）
- November 5 Torii has entered into a License Agreement with BioCryst Pharmaceuticals, Inc. for BCX7353 for the prevention of HAE attacks（PDF）
- September 2 JT Transfers the Marketing Approvals of Six Anti-HIV Drugs in Japan to Gilead Sciences K.K.（PDF）
- July 12 Top-line Results of Phase 3 Clinical Studies of JTZ-951 (enarodustat),in Anemic Patients with Chronic Kidney Disease(Comparative Study) in Japan（PDF）
- July 9 Top-line Results of Phase 3 Clinical Study of Riona®, (ferric citrate hydrate), in Adult Patients with Iron Deficiency Anemia (Comparative Study) in Japan（PDF）
- June 17 Results of Voluntary Retirement Program（PDF）
- May 30 Implementation of Organizational Reform（PDF）
- April 25 Top-line Results of JTE-052 Ointment, JAK inhibitor, Phase 3 Clinical Study in Pediatric Patients with Atopic Dermatitis (Comparative Study) in Japan（PDF）
- March 1 A Presentation on the Phase 3 Clinical Study (Comparative Study) of JTE-052 Ointment, JAK Inhibitor, at the 2019 AAD annual meeting（PDF）
- February 6 Torii has announced the Medium-Term Management Plan 2021（PDF）
- February 6 TRANSFER OF RIGHTS TO protease inhibitor FUTHAN® for injection（PDF）
- January 31 JT Files New Drug Application of JTE-052 Ointment, JAK inhibitor, for the Treatment of Atopic Dermatitis in Japan（PDF）
2018
- December 14 The date for terminating the license agreements by which JT grants Torii the exclusive rights to market the Six Anti-HIV Drugs in Japan has been set（PDF）
- November 29 Torii has agreed with JT to terminate the license agreements by which JT grants Torii the exclusive rights to market the Six Anti-HIV Drugs in Japan（PDF）
- August 27 JT Signs a Letter of Intent to Initiate Discussion to Terminate Agreements on Exclusive Rights to Develop, Commercialize and Market of Six Anti-HIV Drugs in Japan（PDF）
- June 28 JT and Torii Discontinue Development of NK-1 Receptor Antagonist (JTS-661) and Terminate Exclusive License Agreement with Menlo Therapeutics（PDF）
- May 24 Launch of “CEDARCURE® Japanese Cedar Pollen Sublingual Tablets”, an Allergen Immunotherapy Tablet for Japanese Cedar Pollinosis（PDF）
- April 18 Price Listing on the NHI Reimbursement List and Launch of “CEDARCURE® Japanese Cedar Pollen Sublingual Tablets”, an Allergen Immunotherapy Tablet for Japanese Cedar Pollinosis（PDF）
- February 16 Torii receives approval for additional dosage and administration for pediatric indication for MITICURE® House Dust Mite Sublingual Tablets, an Allergen Immunotherapy Tablet for House Dust Mite Allergy（PDF）
- January 12 Top-line Results of the Topical JTE-052 JAK Inhibitor Phase 3 Clinical Study (Comparative Study) in Japan（PDF）
2017
- October 26 JT and Torii Sign Exclusive License Agreement for Development and Commercialization of HIF-PH inhibitor in Japan（PDF）
- October 5 Torii announces Postponement of Price Listing on the NHI Reimbursement List for “CEDARCURE ® Japanese Cedar Pollen Sublingual Tablets”, an Allergen Immunotherapy Tablet for Japanese Cedar Pollinosis（PDF）
- September 27 New Drug Application Approval of “CEDARCURE® Japanese Cedar Pollen Sublingual Tablets”, an Allergen Immunotherapy Tablet for Japanese Cedar Pollinosis（PDF）
- September 22 Toray Receives Japanese Approval for an Additional Indication of Pruritus Treatment REMITCH® CAPSULES 2.5µg and REMITCH® OD Tablets 2.5μg（PDF）
- May 31 Toray’s Pruritus Treatment REMITCH® OD Tablets 2.5 μg to Be Introduced in Japan（PDF）
- March 30 Toray Receives Japanese Approval for an Additional Formulation of Pruritus Treatment REMITCH® OD TABLETS 2.5µg（PDF）
- March 24 Torii files an additional pediatric indication for TO-203 (MITICURE® House Dust Mite Sublingual Tablets), an Allergen Immunotherapy Tablet for House Dust Mite Allergy（PDF）
2016
- December 21 Launch of novel anti-HIV drugs, "Descovy® Combination Tablets LT and HT" in Japan（PDF）
- December 9 JT receives manufacturing and marketing approval of novel anti-HIV drugs, "Descovy® Combination Tablets LT and HT" in Japan（PDF）
- November 21 Eli Lilly Japan and Torii Pharmaceutical launch "Taltz® Subcutaneous Injection 80mg Auto-injector" and "Taltz® Subcutaneous Injection 80mg Syringe" Humanized anti-human IL-17A monoclonal antibody product（PDF）
- October 28 JT and Torii Sign Exclusive License Agreement for Development and Commercialization of JAK Inhibitor in Japan（PDF）
- September 28 Toray Applies for Japanese Approval of Additional Indication of Pruritus Treatment REMITCH® CAPSULES 2.5μg（PDF）
- August 15 JT files New Drug Application for second tenofovir alafenamide (TAF)-based anti-HIV drug in Japan（PDF）
- August 10 JT and Torii Sign Exclusive License Agreement with Menlo Therapeutics for Development and Commercialization of NK-1 Receptor Antagonist in Japan（PDF）
- June 29 Launch of a novel anti-HIV drug "Genvoya® Combination Tablets" in Japan (PDF)
- June 17 JT receives manufacturing and marketing approval of a novel anti-HIV drug, "Genvoya® Combination Tablets" in Japan (PDF)
- April 5 Novel anti-HIV drug Descovy® received US regulatory approval, JT's partner Gilead Sciences announced (PDF)
- March 4 JT files New Drug Application for tenofovir alafenamide (TAF)-based anti-HIV drug in Japan (PDF)
- January 8 Aiming to contribute to psoriasis treatment in Japan, Contract signed for strategic co-promotion for Ixekizumab, Humanized Anti-Interleukin-17 Monoclonal Antibody
2015
- December 25 Torii files a New Drug Application for TO-206, an Allergen Immunotherapy Tablet for Japanese Cedar Pollinosis
- December 18 Announcement of Collaboration of Promotional Activities for Daina screen®・HIV Combo For Human Immunodeficiency Virus Type 1(HIV-1) p24 antigen & antibodies to HIV-1 and HIV- 2 Detection Test Kit
- November 26 Price Listing on the NHI Reimbursement List and Launch of "MITICURE® House Dust Mite Sublingual Tablets" an Allergen Immunotherapy Tablet for House Dust Mite Allergy
-
November 26
Launch of "Allergen Scratch Extract Positive control (Torii) Histamine Dihydrochloride"
in Japan - November 6 Novel anti-HIV drug Genvoya® received US regulatory approval, JT’s partner Gilead Sciences announced
- September 28 New Drug Application Approval of "MITICURE® House Dust Mite Sublingual Tablets" an Allergen Immunotherapy Tablet for House Dust Mite Allergy in Japan
- August 7 Torii announces positive results for the Phase II/III Clinical Study of TO-206, an Allergen Immunotherapy Tablet for Japanese Cedar Pollinosis
- May 20 Toray Receives Japanese Approval for Additional Indication of Pruritus Treatment REMITCH® CAPSULES 2.5 µg and Promotion to Start
- March 3 Toray Applies for Japanese Approval of Additional Indication of Pruritus Treatment REMITCH® CAPSULES 2.5 µg and Notice Regarding Promotion Tie-up
- March 2 JT and Torii sign agreement to market two new tenofovir alafenamide (TAF)-based anti-HIV drugs in Japan
- January 26 Torii files a New Drug Application for TO-203, an Allergen Immunotherapy Tablet for House Dust Mite Allergy
2014
- September 2 Torii announces Price Listing on the NHI Reimbursement List and Launch of "CEDARTOLEN® SUBLINGUAL DROP - Japanese Cedar Pollen" a Sublingual Immunotherapy Drug for Japanese Cedar Pollinosis
- June 16 Torii announces results for the Phase II/III Clinical Study (asthma) of TO-203, an Allergen Immunotherapy Tablet for House Dust Mite Allergy
- April 17 Launch of Riona® Tablets 250mg for the treatment of hyperphosphatemia in Japan
- March 31 Torii announces Postponement of Price Listing on the NHI Reimbursement List for "CEDARTOLEN® SUBLINGUAL DROP - Japanese Cedar Pollen" a Sublingual Immunotherapy Drug for Japanese cedar Pollinosis
- March 10 Torii announces positive results for the Phase II/III Clinical Study of TO-203, an Allergen Immunotherapy Tablet for House Dust Mite Allergy
- January 17 Torii announces the New Drug Application Approval for "CEDARTOLEN® SUBLINGUAL DROP - Japanese Cedar Pollen" a Sublingual Immunotherapy Drug for Japanese cedar Pollinosis, in Japan
- January 17 Riona® Tablets 250mg for the treatment of hyperphosphatemia approved in Japan
2013
- April 25 Launch of a novel anti-HIV drug "Stribild® Combination Tablets" in Japan
- January 29 JT and Torii Sign Licensing Agreement with ALK for Development and Commercialization of Histamine Dihydrochloride Preparation in Japan
- January 7 New Drug Application for marketing approval of JTT-751 (ferric citrate) for the treatment of hyperphosphatemia filed by JT in Japan
2012
- December 25 Torii Files a New Drug Application for TO-194SL, a Sublingual Immunotherapy Drug for Japanese Cedar Pollinosis, in Japan
- September 14 Top-line Results of Phase III Clinical Study of TO-194SL, a Sublingual Immunotherapy Drug for Cedar Pollinosis, in Japan
- August 28 JT and Torii conclude agreement to market novel anti-HIV single-tablet regimen containing JTK-303 (elvitegravir) in Japan
- July 31 Initiation of domestic Phase II/III clinical studies on TO-203, a drug for immunotherapy for house dust mite induced allergic diseases
- April 23 Top-line results of the JTT-751 Phase 3 clinical study in Japan (GBA4-1) for the treatment of hyperphosphatemia
2011
- December 22 Toray, Japan Tobacco and Torii Terminate the Joint Development of nalfurafine hydrochloride ("TRK-820") for Pruritus Associated with Liver Disease in Japan
- February 7 Torii Pharmaceutical to Launch Hyperkalemia Improvement Agent, KAYEXALATE® DRYSYRUP 76%
- January 28 ALK and Torii enter into an exclusive license agreement for allergy immunotherapy products in Japan
2010
2009
- March 23 Launch of REMITCH® CAPSULES 2.5 μg , new oral antipruritus drug
-
January 21
Manufacturing and marketing approval
for REMITCH® CAPSULES 2.5 µg , oral antipruritus drug, in Japan -
January 13
Torii Pharmaceutical to Solely Market Antiemetic Drugs
"Serotone® I.V. Injection 10 mg" and "Serotonereg® Tablets 10 mg"
2007
- December 18 Torii Pharmaceutical and Minophagen Pharmaceutical to Phase Out Basic Trade Agreement
- October 31 Future Marketing and Distribution Organization for Dovonex® Ointment for the Treatment of Psoriasis Vulgaris
- September 26 JT and Torii Sign Licensing Agreement with Keryx for Development and Commercialization of Hyperphosphatemia Drug in Japan
- July 6 Torii Pharmaceutical to Launch Antifungal Agent for External Use, "ZEFNART SOLUTION 2%", in Japan
- June 29 Torii, Toray starts to Co-Promote Hemoperfusion absorption Column "Toraymyxin" for removing endotoxin
2006
- November 28 New Drug Application of Antipruritic Agent "TRK-820" for the Treatment of Severe Pruritus in Hemodialysis Patients in Japan
- September 4 Toray, JT, Torii Agree to Co-Develop and Market TRK-820 Antipruritus Drug for Hepatic Disease Patients in Japan
- August 3 Conclusion of an Agreement over Co-promotion of Dops® for the Treatment of Orthostatic Hypotension
- March 31 Conclusion of Co-marketing Agreement for Dovonex® Ointment for the Treatment of Psoriasis Vulgaris
2005
2004
2003
- November 11 Notice Concerning Completion of Acquisition Company’s Own Shares Through ToSTNet-2
- November 10 Notice Concerning Acquisition of Company’s Own Shares Through ToSTNet-2
- September 1 Termination of Co-promotion Agreement exchanged on Zaditen® with Novaltis Pharma K.K.
- May 8 Notice Concerning Acquisition of the Company’s Own Shares in the Market
- May 8 Notice of Change of Representative Director
- January 28 The Results of Limited-Period Voluntary Early Retirement Program